Hyperkalemia Treatment Market 2027 By Drug Type, Route of Administration, Distribution Channel and Geography | The Insight Partners

Hyperkalemia Treatment Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Drug Type (IV Calcium, Insulin, Sodium Bicarbonate, Beta2 Agonist, Diuretics, Sodium Polystyrene Sulfonate, Others); Route of Administration (Oral, Intravenous, Inhalation, Rectal); Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and Geography

Report Code: TIPRE00015279 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
Covid
MARKET INTRODUCTION

Kidneys regulates the potassium balance in the body by managing its excretion and intake. Dis-functioning of kidney causes the Hyperkalemia disease. It is a type of diseases in which potassium level goes above 3.5-5.0 mmol/L in the blood. Optimum balance of potassium and sodium in the human body is vital for the normal functioning of the myocardium. This disease can occur due to chronic kidney disease, congestive heart failure, or diabetic kidney disease.

MARKET DYNAMICS

Factors driving growth of hyperkalemia treatment market during the forecast period are rising prevalence of kidney disease and cardiac arrhythmias. Also the growing number of laboratories providing creatinine blood tests, kidney functioning test, etc. In 2017, more than 30 million population suffer from chronic kidney diseases in the US. Furthermore, rising incidence of lifestyle-associated diseases is also driving the market. These are the major factors driving the Hyperkalemia Treatment market.

MARKET SCOPE

The "Global Hyperkalemia Treatment Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of Hyperkalemia Treatment Market with detailed market segmentation by Drug Type, Route of Administration, Distribution Channel, and geography. The global Hyperkalemia Treatment market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Hyperkalemia Treatment Market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The global Hyperkalemia Treatment Market is segmented on the Drug Type, Route of Administration, and Distribution Channel. Based on Drug Type, the global Hyperkalemia Treatment Market is segmented into IV Calcium, Insulin, Sodium Bicarbonate, Beta2 Agonist, Diuretics, Sodium Polystyrene Sulfonate, and Others. Based on the Route of Administration, the Hyperkalemia Treatment Market is segmented into Oral, Intravenous, Inhalation, Rectal. Based on the Distribution Channel, the Hyperkalemia Treatment Market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Hyperkalemia Treatment Market based on various segments. It also provides market size and forecast estimates from year 2019 to2027with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Hyperkalemia Treatment Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Hyperkalemia Treatment Market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Hyperkalemia Treatment Market in these regions.



Get more information on this report :

MARKET PLAYERS


The reports cover key developments in the Hyperkalemia Treatment Market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Hyperkalemia Treatment Market are anticipated to lucrative growth opportunities in the future with the rising demand for activated carbon maskin the global market. Below mentioned is the list of fewcompanies engaged in the Hyperkalemia Treatment Market.

The report also includes the profiles of key Hyperkalemia Treatment Market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •  AstraZeneca
  •  Klarvoyant Biogenics Pvt. Ltd
  •  Concordia Pharmaceuticals Inc
  •  Steadfast MediShield Pvt. Ltd
  •  Perrigo Company plc
  •  AdvaCare Pharma
  •  Eli Lilly and Company
  •  Carolina Medical Products
  •  Relypsa, Inc.
  •  RSM Kilitch Pharma Pvt. Ltd

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Hyperkalemia Treatment Market - By Drug Type
1.3.2 Hyperkalemia Treatment Market - By Route of Administration
1.3.3 Hyperkalemia Treatment Market - By Distribution Channel
1.3.4 Hyperkalemia Treatment Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. HYPERKALEMIA TREATMENT MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. HYPERKALEMIA TREATMENT MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. HYPERKALEMIA TREATMENT MARKET - GLOBAL MARKET ANALYSIS
6.1. HYPERKALEMIA TREATMENT - GLOBAL MARKET OVERVIEW
6.2. HYPERKALEMIA TREATMENT - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. HYPERKALEMIA TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - DRUG TYPE
7.1. OVERVIEW
7.2. DRUG TYPE MARKET FORECASTS AND ANALYSIS
7.3. IV CALCIUM
7.3.1. Overview
7.3.2. IV Calcium Market Forecast and Analysis
7.4. INSULIN
7.4.1. Overview
7.4.2. Insulin Market Forecast and Analysis
7.5. SODIUM BICARBONATE
7.5.1. Overview
7.5.2. Sodium Bicarbonate Market Forecast and Analysis
7.6. BETA2 AGONIST
7.6.1. Overview
7.6.2. Beta2 Agonist Market Forecast and Analysis
7.7. DIURETICS
7.7.1. Overview
7.7.2. Diuretics Market Forecast and Analysis
7.8. SODIUM POLYSTYRENE SULFONATE
7.8.1. Overview
7.8.2. Sodium Polystyrene Sulfonate Market Forecast and Analysis
7.9. OTHERS
7.9.1. Overview
7.9.2. Others Market Forecast and Analysis
8. HYPERKALEMIA TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - ROUTE OF ADMINISTRATION
8.1. OVERVIEW
8.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
8.3. ORAL
8.3.1. Overview
8.3.2. Oral Market Forecast and Analysis
8.4. INTRAVENOUS
8.4.1. Overview
8.4.2. Intravenous Market Forecast and Analysis
8.5. INHALATION
8.5.1. Overview
8.5.2. Inhalation Market Forecast and Analysis
8.6. RECTAL
8.6.1. Overview
8.6.2. Rectal Market Forecast and Analysis
9. HYPERKALEMIA TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
9.3. HOSPITAL PHARMACY
9.3.1. Overview
9.3.2. Hospital Pharmacy Market Forecast and Analysis
9.4. RETAIL PHARMACY
9.4.1. Overview
9.4.2. Retail Pharmacy Market Forecast and Analysis
9.5. ONLINE PHARMACY
9.5.1. Overview
9.5.2. Online Pharmacy Market Forecast and Analysis
10. HYPERKALEMIA TREATMENT MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Hyperkalemia Treatment Market Overview
10.1.2 North America Hyperkalemia Treatment Market Forecasts and Analysis
10.1.3 North America Hyperkalemia Treatment Market Forecasts and Analysis - By Drug Type
10.1.4 North America Hyperkalemia Treatment Market Forecasts and Analysis - By Route of Administration
10.1.5 North America Hyperkalemia Treatment Market Forecasts and Analysis - By Distribution Channel
10.1.6 North America Hyperkalemia Treatment Market Forecasts and Analysis - By Countries
10.1.6.1 United States Hyperkalemia Treatment Market
10.1.6.1.1 United States Hyperkalemia Treatment Market by Drug Type
10.1.6.1.2 United States Hyperkalemia Treatment Market by Route of Administration
10.1.6.1.3 United States Hyperkalemia Treatment Market by Distribution Channel
10.1.6.2 Canada Hyperkalemia Treatment Market
10.1.6.2.1 Canada Hyperkalemia Treatment Market by Drug Type
10.1.6.2.2 Canada Hyperkalemia Treatment Market by Route of Administration
10.1.6.2.3 Canada Hyperkalemia Treatment Market by Distribution Channel
10.1.6.3 Mexico Hyperkalemia Treatment Market
10.1.6.3.1 Mexico Hyperkalemia Treatment Market by Drug Type
10.1.6.3.2 Mexico Hyperkalemia Treatment Market by Route of Administration
10.1.6.3.3 Mexico Hyperkalemia Treatment Market by Distribution Channel
10.2. EUROPE
10.2.1 Europe Hyperkalemia Treatment Market Overview
10.2.2 Europe Hyperkalemia Treatment Market Forecasts and Analysis
10.2.3 Europe Hyperkalemia Treatment Market Forecasts and Analysis - By Drug Type
10.2.4 Europe Hyperkalemia Treatment Market Forecasts and Analysis - By Route of Administration
10.2.5 Europe Hyperkalemia Treatment Market Forecasts and Analysis - By Distribution Channel
10.2.6 Europe Hyperkalemia Treatment Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Hyperkalemia Treatment Market
10.2.6.1.1 Germany Hyperkalemia Treatment Market by Drug Type
10.2.6.1.2 Germany Hyperkalemia Treatment Market by Route of Administration
10.2.6.1.3 Germany Hyperkalemia Treatment Market by Distribution Channel
10.2.6.2 France Hyperkalemia Treatment Market
10.2.6.2.1 France Hyperkalemia Treatment Market by Drug Type
10.2.6.2.2 France Hyperkalemia Treatment Market by Route of Administration
10.2.6.2.3 France Hyperkalemia Treatment Market by Distribution Channel
10.2.6.3 Italy Hyperkalemia Treatment Market
10.2.6.3.1 Italy Hyperkalemia Treatment Market by Drug Type
10.2.6.3.2 Italy Hyperkalemia Treatment Market by Route of Administration
10.2.6.3.3 Italy Hyperkalemia Treatment Market by Distribution Channel
10.2.6.4 Spain Hyperkalemia Treatment Market
10.2.6.4.1 Spain Hyperkalemia Treatment Market by Drug Type
10.2.6.4.2 Spain Hyperkalemia Treatment Market by Route of Administration
10.2.6.4.3 Spain Hyperkalemia Treatment Market by Distribution Channel
10.2.6.5 United Kingdom Hyperkalemia Treatment Market
10.2.6.5.1 United Kingdom Hyperkalemia Treatment Market by Drug Type
10.2.6.5.2 United Kingdom Hyperkalemia Treatment Market by Route of Administration
10.2.6.5.3 United Kingdom Hyperkalemia Treatment Market by Distribution Channel
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Hyperkalemia Treatment Market Overview
10.3.2 Asia-Pacific Hyperkalemia Treatment Market Forecasts and Analysis
10.3.3 Asia-Pacific Hyperkalemia Treatment Market Forecasts and Analysis - By Drug Type
10.3.4 Asia-Pacific Hyperkalemia Treatment Market Forecasts and Analysis - By Route of Administration
10.3.5 Asia-Pacific Hyperkalemia Treatment Market Forecasts and Analysis - By Distribution Channel
10.3.6 Asia-Pacific Hyperkalemia Treatment Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Hyperkalemia Treatment Market
10.3.6.1.1 Australia Hyperkalemia Treatment Market by Drug Type
10.3.6.1.2 Australia Hyperkalemia Treatment Market by Route of Administration
10.3.6.1.3 Australia Hyperkalemia Treatment Market by Distribution Channel
10.3.6.2 China Hyperkalemia Treatment Market
10.3.6.2.1 China Hyperkalemia Treatment Market by Drug Type
10.3.6.2.2 China Hyperkalemia Treatment Market by Route of Administration
10.3.6.2.3 China Hyperkalemia Treatment Market by Distribution Channel
10.3.6.3 India Hyperkalemia Treatment Market
10.3.6.3.1 India Hyperkalemia Treatment Market by Drug Type
10.3.6.3.2 India Hyperkalemia Treatment Market by Route of Administration
10.3.6.3.3 India Hyperkalemia Treatment Market by Distribution Channel
10.3.6.4 Japan Hyperkalemia Treatment Market
10.3.6.4.1 Japan Hyperkalemia Treatment Market by Drug Type
10.3.6.4.2 Japan Hyperkalemia Treatment Market by Route of Administration
10.3.6.4.3 Japan Hyperkalemia Treatment Market by Distribution Channel
10.3.6.5 South Korea Hyperkalemia Treatment Market
10.3.6.5.1 South Korea Hyperkalemia Treatment Market by Drug Type
10.3.6.5.2 South Korea Hyperkalemia Treatment Market by Route of Administration
10.3.6.5.3 South Korea Hyperkalemia Treatment Market by Distribution Channel
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Hyperkalemia Treatment Market Overview
10.4.2 Middle East and Africa Hyperkalemia Treatment Market Forecasts and Analysis
10.4.3 Middle East and Africa Hyperkalemia Treatment Market Forecasts and Analysis - By Drug Type
10.4.4 Middle East and Africa Hyperkalemia Treatment Market Forecasts and Analysis - By Route of Administration
10.4.5 Middle East and Africa Hyperkalemia Treatment Market Forecasts and Analysis - By Distribution Channel
10.4.6 Middle East and Africa Hyperkalemia Treatment Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Hyperkalemia Treatment Market
10.4.6.1.1 South Africa Hyperkalemia Treatment Market by Drug Type
10.4.6.1.2 South Africa Hyperkalemia Treatment Market by Route of Administration
10.4.6.1.3 South Africa Hyperkalemia Treatment Market by Distribution Channel
10.4.6.2 Saudi Arabia Hyperkalemia Treatment Market
10.4.6.2.1 Saudi Arabia Hyperkalemia Treatment Market by Drug Type
10.4.6.2.2 Saudi Arabia Hyperkalemia Treatment Market by Route of Administration
10.4.6.2.3 Saudi Arabia Hyperkalemia Treatment Market by Distribution Channel
10.4.6.3 U.A.E Hyperkalemia Treatment Market
10.4.6.3.1 U.A.E Hyperkalemia Treatment Market by Drug Type
10.4.6.3.2 U.A.E Hyperkalemia Treatment Market by Route of Administration
10.4.6.3.3 U.A.E Hyperkalemia Treatment Market by Distribution Channel
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Hyperkalemia Treatment Market Overview
10.5.2 South and Central America Hyperkalemia Treatment Market Forecasts and Analysis
10.5.3 South and Central America Hyperkalemia Treatment Market Forecasts and Analysis - By Drug Type
10.5.4 South and Central America Hyperkalemia Treatment Market Forecasts and Analysis - By Route of Administration
10.5.5 South and Central America Hyperkalemia Treatment Market Forecasts and Analysis - By Distribution Channel
10.5.6 South and Central America Hyperkalemia Treatment Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Hyperkalemia Treatment Market
10.5.6.1.1 Brazil Hyperkalemia Treatment Market by Drug Type
10.5.6.1.2 Brazil Hyperkalemia Treatment Market by Route of Administration
10.5.6.1.3 Brazil Hyperkalemia Treatment Market by Distribution Channel
10.5.6.2 Argentina Hyperkalemia Treatment Market
10.5.6.2.1 Argentina Hyperkalemia Treatment Market by Drug Type
10.5.6.2.2 Argentina Hyperkalemia Treatment Market by Route of Administration
10.5.6.2.3 Argentina Hyperkalemia Treatment Market by Distribution Channel
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL HYPERKALEMIA TREATMENT MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Rest of the World
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. HYPERKALEMIA TREATMENT MARKET, KEY COMPANY PROFILES
13.1. ASTRAZENECA
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. KLARVOYANT BIOGENICS PVT. LTD
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. CONCORDIA PHARMACEUTICALS INC
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. STEADFAST MEDISHIELD PVT. LTD
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. PERRIGO COMPANY PLC
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. ADVACARE PHARMA
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. ELI LILLY AND COMPANY
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. CAROLINA MEDICAL PRODUCTS
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. RELYPSA, INC.
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. RSM KILITCH PHARMA PVT. LTD
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
13.11. NOVEL LABORATORIE
13.11.1. Key Facts
13.11.2. Business Description
13.11.3. Products and Services
13.11.4. Financial Overview
13.11.5. SWOT Analysis
13.11.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
The List of Companies

1. AstraZeneca
2. Klarvoyant Biogenics Pvt. Ltd
3. Concordia Pharmaceuticals Inc
4. Steadfast MediShield Pvt. Ltd
5. Perrigo Company plc
6. AdvaCare Pharma
7. Eli Lilly and Company
8. Carolina Medical Products
9. Relypsa, Inc.
10. RSM Kilitch Pharma Pvt. Ltd
TIPRE00015279
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking